FTSE 100 ends higher as AstraZeneca offsets commodity losses



(For a Reuters live blog on U.S., UK and European stock markets, click

or type LIVE/ in a news window)

* AstraZeneca jumps on positive cancer drug update

* Focus on UK labour, CPI data later this week

* FTSE 100 up 0.1%, FTSE 250 adds 0.2% (Updates with market close)

By Sruthi Shankar and Aniruddha Ghosh

Aug 15 (Reuters) - Britain's blue-chip share index ended higher on Monday, as gains in drugmaker AstraZeneca and consumer stocks relieved pressure from losses in mining and oil heavyweights after data showed China's economy unexpectedly slowed last month.

The FTSE 100 .FTSE rose 0.1% to hold near 10-week highs, while the midcap FTSE 250 index .FTMC climbed 0.2%.

The mood was sombre across global stock markets, with investors turning to defensive sectors such as healthcare and consumer staples amid worries about the health of the world's second-largest economy.

"People are going to be worried a whole lot over the global economy," said Capital Economics' Oliver Allen.

"So if you're looking at things through that kind of risk premia, that's a bit worse for energy, materials, financials and some of the things that the FTSE 100 specialises in."

The FTSE 100 has outperformed its global peers this year due to its large exposure to commodity stocks that have surged on the back of a jump in oil and metal prices. A weakening pound has also boosted dollar earners in the index.

The FTSE 100 is up nearly 2% so far this year, while the MSCI world equities index .MIWD00000PUS has shed almost 13%.

Oil major Shell SHEL.L and miners Rio Tinto RIO.L and Anglo American AAL.L slipped on Monday, in tandem with weaker commodity prices, after data from China data raised fears about weakening demand.

Investors are awaiting the British employment report as well as consumer prices data later this week to gauge the state of the labour market and inflation.

The data could offer clues on whether the Bank of England opts for a second consecutive 50 basis points rate hike at its September meeting.

AstraZeneca AZN.L gained 2.3% after the drugmaker said its cancer drug, Enhertu, developed with Japan's Daiichi Sankyo 4568.T delayed the progression of a form of advanced breast cancer in previously treated patients.
Reporting by Sruthi Shankar and Aniruddha Ghosh in Bengaluru; editing by Uttaresh.V, Vinay Dwivedi and Alex Richardson

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.